Selvakumar Subbian

List of Publications by Year
in descending order

89 papers	3,269 citations	159585 30 h-index	182427 51 g-index
99 all docs	99 docs citations	99 times ranked	3918 citing authors

#	Article	IF	Citations
1	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion on Therapeutic Targets, 2022, 26, 13-28.	3.4	5
2	COVID-19 and cancer: start the resolution!. Cancer and Metastasis Reviews, 2022, 41, 1-15.	5.9	5
3	Liposomal Glutathione Helps to Mitigate Mycobacterium tuberculosis Infection in the Lungs. Antioxidants, 2022, 11, 673.	5.1	7
4	An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy. Scientific Reports, 2022, 12, 3794.	3.3	14
5	SARSâ€CoVâ€2, SARSâ€CoV, and MERSâ€CoV encode circular RNAs of spliceosomeâ€independent origin. Journal of Medical Virology, 2022, 94, 3203-3222.	5.0	17
6	An Update on Tuberculosis Vaccines. Methods in Molecular Biology, 2022, 2410, 387-409.	0.9	6
7	Human Macrophages Exhibit GM-CSF Dependent Restriction of Mycobacterium tuberculosis Infection via Regulating Their Self-Survival, Differentiation and Metabolism. Frontiers in Immunology, 2022, 13, .	4.8	3
8	Comprehensive Analysis of Disease Pathology in Immunocompetent and Immunocompromised Hosts following Pulmonary SARS-CoV-2 Infection. Biomedicines, 2022, 10, 1343.	3.2	11
9	Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection. MBio, 2022, 13, .	4.1	17
10	3D host cell and pathogen-based bioassay development for testing anti-tuberculosis (TB) drug response and modeling immunodeficiency. Biomolecular Concepts, 2021, 12, 117-128.	2.2	3
11	Inactivation and Elimination of SARS-CoV-2 in Biosamples Using Simple Fixatives and Ultrafiltration. Methods and Protocols, 2021, 4, 18.	2.0	9
12	Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis. International Journal of Molecular Sciences, 2021, 22, 3773.	4.1	52
13	Extrapulmonary Tuberculosisâ€"An Update on the Diagnosis, Treatment and Drug Resistance. Journal of Respiration, 2021, 1, 141-164.	1.1	27
14	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses, 2021, 13, 1246.	3.3	35
15	Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clinical Microbiology Reviews, 2021, 34, .	13.6	141
16	Erratum for Ramasamy and Subbian, â€œCritical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesisâ€. Clinical Microbiology Reviews, 2021, 34, e0016321.	13.6	21
17	Editorial: Host-Directed Therapies for Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 742053.	3.9	1
18	Effects of Glutathione Diminishment on the Immune Responses against Mycobacterium tuberculosis Infection. Applied Sciences (Switzerland), 2021, 11, 8274.	2.5	6

#	Article	IF	Citations
19	In Vitro Miniaturized Tuberculosis Spheroid Model. Biomedicines, 2021, 9, 1209.	3.2	4
20	The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities. Journal of Respiration, 2021, 1, 49-59.	1.1	5
21	Everolimus-induced effector mechanism in macrophages and survivability of Erdman, CDC1551 and HN878 strains of <i>Mycobacterium tuberculosis</i> infection. Biomolecular Concepts, 2021, 12, 46-54.	2.2	3
22	Eicosanoid regulation of debris-stimulated metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	12
23	Immune Correlates of Non-Necrotic and Necrotic Granulomas in Pulmonary Tuberculosis: A Pilot Study. Journal of Respiration, 2021, 1, 248-259.	1.1	5
24	The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis. , 2021, , 275-282.		0
25	Aggregation state of Mycobacterium tuberculosis impacts host immunity and augments pulmonary disease pathology. Communications Biology, 2021, 4, 1256.	4.4	12
26	Unmethylated CpG motif-containing genomic DNA fragment of Bacillus calmette-guerin promotes macrophage functions through TLR9-mediated activation of NF-Î°B and MAPKs signaling pathways. Innate Immunity, 2020, 26, 183-203.	2.4	8
27	The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air. Vaccines, 2020, 8, 612.	4.4	9
28	BCG Vaccination of Infants Confers <i>Mycobacterium tuberculosis</i> Strain-Specific Immune Responses by Leukocytes. ACS Infectious Diseases, 2020, 6, 3141-3146.	3.8	5
29	GM-CSF Dependent Differential Control of Mycobacterium tuberculosis Infection in Human and Mouse Macrophages: Is Macrophage Source of GM-CSF Critical to Tuberculosis Immunity?. Frontiers in Immunology, 2020, 11, 1599.	4.8	17
30	Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study. Frontiers in Pharmacology, 2020, 11, 1103.	3.5	1
31	Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. Current HIV Research, 2020, 18, 19-28.	0.5	9
32	Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis. Microbes and Infection, 2020, 22, 423-431.	1.9	9
33	Of tuberculosis and non-tuberculous mycobacterial infections â€" a comparative analysis of epidemiology, diagnosis and treatment. Journal of Biomedical Science, 2020, 27, 74.	7.0	123
34	An improved protocol to establish experimental tuberculous meningitis in the rabbit. MethodsX, 2020, 7, 100832.	1.6	3
35	Inoculum size and traits of the infecting clinical strain define the protection level against <i>Mycobacterium tuberculosis</i> infection in a rabbit model. European Journal of Immunology, 2020, 50, 858-872.	2.9	13
36	Dual RNA-seq of Orientia tsutsugamushi informs on host-pathogen interactions for this neglected intracellular human pathogen. Nature Communications, 2020, 11, 3363.	12.8	39

#	Article	IF	Citations
37	Antimycobacterial Effects of Everolimus in a Human Granuloma Model. Journal of Clinical Medicine, 2020, 9, 2043.	2.4	26
38	Effect of Iron Supplementation on the Outcome of Non-Progressive Pulmonary Mycobacterium tuberculosis Infection. Journal of Clinical Medicine, 2019, 8, 1155.	2.4	8
39	Immunometabolism of Phagocytes During Mycobacterium tuberculosis Infection. Frontiers in Molecular Biosciences, 2019, 6, 105.	3.5	65
40	Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. International Journal of Infectious Diseases, 2019, 84, 15-21.	3.3	7
41	Adipose Tissue Regulates Pulmonary Pathology during TB Infection. MBio, 2019, 10, .	4.1	27
42	Biphasic Dynamics of Macrophage Immunometabolism during<i>Mycobacterium tuberculosis</i>Infection. MBio, 2019, 10, .	4.1	101
43	Differential Culturability of Mycobacterium tuberculosis in Culture-Negative Sputum of Patients With Pulmonary Tuberculosis and in a Simulated Model of Dormancy. Frontiers in Microbiology, 2019, 10, 2381.	3.5	31
44	Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model. Frontiers in Cellular and Infection Microbiology, 2019, 9, 450.	3.9	16
45	Role of the inositol pyrophosphate multikinase Kcs1 in Cryptococcus inositol metabolism. Fungal Genetics and Biology, 2018, 113, 42-51.	2.1	5
46	Effect of Mycobacterium tuberculosis infection on adipocyte physiology. Microbes and Infection, 2018, 20, 81-88.	1.9	21
47	The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against Mycobacterium tuberculosis. Frontiers in Immunology, 2018, 9, 2069.	4.8	38
48	Granulomatous Response to Mycobacterium tuberculosis Infection. , 2018, , 41-66.		2
49	Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific. PLoS Pathogens, 2018, 14, e1007223.	4.7	75
50	The wide utility of rabbits as models of human diseases. Experimental and Molecular Medicine, 2018, 50, 1-10.	7.7	103
51	Harnessing the mTOR Pathway for Tuberculosis Treatment. Frontiers in Microbiology, 2018, 9, 70.	3.5	71
52	Animal Models of Tuberculosis. , 2018, , 67-97.		3
53	The Capacity of <i>Mycobacterium tuberculosis</i> To Survive Iron Starvation Might Enable It To Persist in Iron-Deprived Microenvironments of Human Granulomas. MBio, 2017, 8, .	4.1	116
54	Host-Directed Therapeutic Strategies for Tuberculosis. Frontiers in Medicine, 2017, 4, 171.	2.6	109

#	Article	IF	Citations
55	IFN-Îµ protects primary macrophages against HIV infection. JCI Insight, 2016, 1, e88255.	5.0	30
56	Immunometabolism in Tuberculosis. Frontiers in Immunology, 2016, 7, 150.	4.8	82
57	Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis. Frontiers in Immunology, 2016, 7, 238.	4.8	29
58	Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model. EBioMedicine, 2016, 4, 104-114.	6.1	59
59	Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infection, Genetics and Evolution, 2016, 45, 474-492.	2.3	165
60	Development of immune-biomarkers of pulmonary tuberculosis in a rabbit model. Tuberculosis, 2016, 101, 1-7.	1.9	14
61	Experimental Evolution of Mycobacterium tuberculosis in Human Macrophages Results in Low-Frequency Mutations Not Associated with Selective Advantage. PLoS ONE, 2016, 11, e0167989.	2.5	6
62	Vaccination with an Attenuated Ferritin Mutant Protects Mice against Virulent<i>Mycobacterium tuberculosis</i>. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	21
63	Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study. PLoS ONE, 2015, 10, e0132249.	2.5	83
64	Extent of Spine Deformity Predicts Lung Growth and Function in Rabbit Model of Early Onset Scoliosis. PLoS ONE, 2015, 10, e0136941.	2.5	13
65	Etanercept Exacerbates Inflammation and Pathology in a Rabbit Model of Active Pulmonary Tuberculosis. Journal of Interferon and Cytokine Research, 2014, 34, 716-726.	1.2	22
66	Cryptococcus inositol utilization modulates the host protective immune response during brain infection. Cell Communication and Signaling, 2014, 12, 51.	6.5	23
67	Detection of Mycobacterium tuberculosis in latently infected lungs by immunohistochemistry and confocal microscopy. Journal of Medical Microbiology, 2014, 63, 1432-1435.	1.8	19
68	Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis. Cell Communication and Signaling, 2013, 11, 16.	6.5	37
69	Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Communication and Signaling, 2013, 11, 60.	6.5	81
70	Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to <i>Mycobacterium tuberculosis</i>. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2997-3006.	7.1	120
71	Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection. PLoS ONE, 2013, 8, e74082.	2.5	43
72	Spontaneous Latency in a Rabbit Model of Pulmonary Tuberculosis. American Journal of Pathology, 2012, 181, 1711-1724.	3.8	67

#	Article	IF	Citations
73	Strain specific transcriptional response in Mycobacterium tuberculosis infected macrophages. Cell Communication and Signaling, 2012, 10, 2.	6.5	73
74	Phosphodiesterase-4 Inhibition Combined with Isoniazid Treatment of Rabbits with Pulmonary Tuberculosis Reduces Macrophage Activation and Lung Pathology. American Journal of Pathology, 2011, 179, 289-301.	3.8	83
75	Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biology, 2011, 1, 110016.	3.6	99
76	Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid â€“ Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs. PLoS Pathogens, 2011, 7, e1002262.	4.7	83
77	Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice. PLoS ONE, 2011, 6, e17091.	2.5	67
78	Imaging tuberculosis with endogenous Î²-lactamase reporter enzyme fluorescence in live mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12239-12244.	7.1	168
79	<i>Mycobacterium tuberculosis</i>Interferes with the Response to Infection by Inducing the Host EphA2 Receptor. Journal of Infectious Diseases, 2009, 199, 1797-1806.	4.0	19
80	Protection of<i>Mycobacterium tuberculosis</i>from Reactive Oxygen Species Conferred by the<i>mel2</i>Locus Impacts Persistence and Dissemination. Infection and Immunity, 2009, 77, 2557-2567.	2.2	57
81	Application of optical imaging to study of extrapulmonary spread by tuberculosis. Tuberculosis, 2009, 89, S15-S17.	1.9	31
82	Construction and evaluation of luciferase reporter phages for the detection of active and non-replicating tubercle bacilli. Journal of Microbiological Methods, 2008, 73, 18-25.	1.6	35
83	Use of Gene Dosage Effects for a Whole-Genome Screen To Identify <i>Mycobacterium marinum</i> Macrophage Infection Loci. Infection and Immunity, 2008, 76, 3100-3115.	2.2	6
84	A Mycobacterium marinum mel2 Mutant Is Defective for Growth in Macrophages That Produce Reactive Oxygen and Reactive Nitrogen Species. Infection and Immunity, 2007, 75, 127-134.	2.2	29
85	Identification and characterization of the regulatory elements of the inducible acetamidase operon from Mycobacterium smegmatis. Canadian Journal of Microbiology, 2007, 53, 599-606.	1.7	3
86	The Mycobacterium marinum mel2 locus displays similarity to bacterial bioluminescence systems and plays a role in defense against reactive oxygen and nitrogen species. BMC Microbiology, 2007, 7, 4.	3.3	29
87	Identification of Mycobacterium marinum macrophage infection mutants. Microbial Pathogenesis, 2006, 40, 139-151.	2.9	31
88	Identification of Two Mycobacterium marinum Loci That Affect Interactions with Macrophages. Infection and Immunity, 2004, 72, 6902-6913.	2.2	38
89	L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model. Frontiers in Pharmacology, 0, 13, .	3.5	8